Relationship between early use of tocilizumab during chimeric antigen receptor T-cell therapy for multiple myeloma and cardiovascular risk and progression-free survival.
- DOI
- 10.1093/ehjopen/oeag097
- Published
- 2026 May
- Container
- European heart journal open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ehjopen/oeag097,
title = {Relationship between early use of tocilizumab during chimeric antigen receptor T-cell therapy for multiple myeloma and cardiovascular risk and progression-free survival.},
author = {Golec S and Fu W and Moshier E and Peleg A and Pileggi B and Rossi A and Sahni G},
year = {2026},
journal = {European heart journal open},
doi = {10.1093/ehjopen/oeag097},
url = {https://doi.org/10.1093/ehjopen/oeag097}
}RIS
TY - JOUR TI - Relationship between early use of tocilizumab during chimeric antigen receptor T-cell therapy for multiple myeloma and cardiovascular risk and progression-free survival. AU - Golec S AU - Fu W AU - Moshier E AU - Peleg A AU - Pileggi B AU - Rossi A AU - Sahni G PY - 2026 JO - European heart journal open DO - 10.1093/ehjopen/oeag097 UR - https://doi.org/10.1093/ehjopen/oeag097 ER -
APA
S, G., W, F., E, M., A, P., B, P., A, R., & G, S. (2026). Relationship between early use of tocilizumab during chimeric antigen receptor T-cell therapy for multiple myeloma and cardiovascular risk and progression-free survival.. European heart journal open. https://doi.org/10.1093/ehjopen/oeag097
Source records
- pubmed · retrieved 2026-09-26T08:32:58.889Z
- europe-pmc · retrieved 2026-09-26T08:32:58.903Z